While Phase 1 (NCT03294694, NCT02897375) and Phase 2 (NCT02657928) trials of CDK4/6 inhibition in combination with other therapies in ovarian cancer have recently opened, no data is available yet from these studies. This evidence concerns the gene CDK4 and ovarian carcinoma.